QuintilesIMS has entered into a strategic collaboration with the national Cancer Vanguard to contribute its anonymised patient level, real world data on drug usage treatment costs and outcomes to extend the capabilities of the body.
The collaboration aims to seamlessly infuse QuintilesIMS insights into practice management to optimise medicines use, and to use real world data to transform the colorectal cancer patient pathway to improve clinical outcomes and patient experience.
Stephen Jowett, country lead, health system engagement UK, QuintilesIMS, said: “We are thrilled to have been given this opportunity. It is hugely exciting to be at the forefront of new strategies for cancer and to be aligning on ideas put forward by the Five Year Forward View. The partnership has a clear goal and that is to improve patient outcomes in CRC and we believe this is the first step to achieving this.”
QuintilesIMS was one of four companies so far selected through the NHS Cancer Vanguard Pharma Challenge. Amgen and Sandoz are two of the other companies selected. The Amgen project aims to map out and measure the most efficient out-of-hospital administration of Xgeva (denosumab), which is used in patients with advanced breast cancer. Meanwhile, Sandoz has proposed an education and engagement programme with healthcare professionals across the Cancer Vanguard about the use of biosimilar medicines.
The QuintilesIMS project also represents a new approach to partnership working with the Cancer Vanguard, Merck, and a patient data capture platform uMotif. The project will use technology provided by QuintilesIMS via its strategic collaboration with uMotif to support the Vanguard’s understanding of the patient experience and inform the care pathway redesign.
The Cancer Vanguard works across a total population of 10.7 million people, aiming to transform and create new models of cancer care that can be reproduced nationally. The Vanguard is a partnership led by three organisations: The Christie NHS Foundation Trust, The Royal Marsden NHS Foundation Trust, and University College London Hospitals NHS Foundation Trust.